Loading…
← CockpitCompetitor Analysis › 6620.TWO Handa Pharmaceuticals IncOpen in the cockpit ↗

Handa Pharmaceuticals Inc6620.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum leader 95
Mkt cap
$469M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$10.7M
20-day average traded
Fwd P/E
24.9×
forward earnings
ROIC−WACC
-1.9 pp
WACC 6.3%
Hurdle
-102 pp
Req g minus delivered
Next earnings
120 days
18 Mar 2027
Close · TWDNT$101.50
1D-6.5%
1W-25.6%
1M-29.3%
3M+31.1%
6M+45.0%
YTD+18.0%
1Y-15.1%
ATR %10.6%
52w lowhigh34.5% off high

What Handa Pharmaceuticals does

No business profile yet.

Handa Pharmaceuticals at a glance

Size Handa Pharmaceuticals (6620.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $469M, the 450th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$101.50 on 18 Nov 2026.

Performance Over six months the shares gained 45.0%, against -9.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue fell 15.9% over the last twelve months (peer median +13.0%); the operating margin is 29.8% (peer median 0.1%).

Valuation It trades at 24.9× forward earnings against a peer median of 25.9× (3rd cheapest of 5).

Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +127%, so the hurdle is -102 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.9 points below its cost of capital (6.3% WACC).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 20266620.TWO 140Peer median 89
Six months, rebased to 100: Handa Pharmaceuticals against the median of its 20 peers (local-currency closes).

Handa Pharmaceuticals financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$930MNT$1.73BNT$831MNT$1.11BNT$198M
Revenue growth—+108%-25%+460%—
Gross profitNT$881MNT$1.45BNT$819MNT$1.09BNT$164M
EBITDAn/aNT$1.10BNT$428MNT$706M-NT$72.9M
Net incomeNT$298MNT$750MNT$473MNT$727M-NT$40.0M
Free cash flown/aNT$227MNT$490MNT$667M-NT$212M
Capital expendituren/aNT$17.1MNT$7.77MNT$944,000NT$758,000
Total debtn/aNT$47.6MNT$40.1MNT$13.2MNT$29.6M

Quarterly statements and history in the cockpit →

Handa Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%EOLS002370CAPRKPL3012013705002693AQSTSMSPHARMA600624HNSAASMBRGNX003020GUFICBIO3005843012776620.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Handa Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%20×30×40×EOLSSMSPHARMA0030206035666620.TWORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Handa Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%3705002693HNSA3005843012776620.TWOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Handa Pharmaceuticals is the large dot.

Handa Pharmaceuticals competitors and peer comparison

How Handa Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Handa Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure6620.TWOPeer medianRank in peer set
1-month return-29.3%-2.1%lowest of 21
6-month return+45.0%-9.3%3rd highest of 20
Distance from 52-week high-34.5%-39.2%9th highest of 21
Revenue growth (TTM)-15.9%+13.0%2nd lowest of 20
Operating margin29.8%0.1%highest of 19
Forward P/E24.9×25.9×3rd cheapest of 5
Growth the price implies (Req g, 7 yrs)24.8%3.9%2nd most demanding of 7
Growth delivered (Del g)+126.7%+2.1%highest of 7
Hurdle (Req g minus delivered)-101.9 pp+0.5 pp2nd least demanding of 7
ROIC minus cost of capital-1.9 pp-5.4 pp8th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%24.9×24.8%+126.7%
Evolus EOLSUnited States$468M+7%+14%-5%28.5×n/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%n/an/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%n/an/an/a
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%n/an/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%n/a-3.8%+0.7%
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%n/a44.1%+1.0%
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%n/an/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%42.2×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%n/an/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%n/a-4.7%+105.3%
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%n/an/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%n/an/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%n/an/an/a
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%18.2×n/an/a
Gufic Biosciences GUFICBIO.NSIndia$452M+48%+17%14%n/an/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%n/a3.3%-1.1%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%n/a8.9%+9.1%
Pulike Biological Engineering 603566.SSChina$449M-21%-9%5%23.2×4.5%+3.3%

Questions

Which companies are Handa Pharmaceuticals's closest peers?
The cockpit's peer set: Evolus (EOLS), Zhejiang Yatai Pharmaceutical (002370.SZ), Capricor Therapeutics (CAPR), Kwality Pharmaceuticals (KPL.NS), ChengDa PharmaCeuticals (301201.SZ), YungShin Global (3705.TW), Hainan Shuangcheng Pharmaceuticals (002693.SZ), BlossomHill Therapeutics (BLSM).
Is Handa Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 24.9× against a peer median of 25.9×, 3rd cheapest of 5 in its peer set. For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +127%, so the hurdle is -102 pp: the price already allows for a slowdown.
How has Handa Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +45.0% against -9.3% for the median peer; over one year -15.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.